U-VUE Biomarker Datasheet - TIGIT

Target:TIGIT
Alternative Name:T-cell immunoreceptor with Ig and ITIM domains
Clone:BLR047F
Isotype:Rabbit IgG
Reactivity:Human
Main cell types:Lymphocytes
Subcellular Location:Plasma Membrane
Positive control:Tonsil, Spleen

TIGIT is a emerging immune checkpoint receptor expressed on T cells and NK cells. TIGIT is a negative regulator of cytotoxic lymphocytes and has been observed up-regulated in various malignancies. Due to its broad expression on lymphocytes, TIGIT may prevent tumour antigen release by NK cells, impair T cell priming by DCs or inhibit cancer cell killing by CD8+ T cells. Inhibition of TIGIT may restore anti-tumor T cell activity through competition with its costimulatory receptor, CD226.

IHC: Anti-TIGIT antibody [BLR047F] staining normal tonsil FFPE tissue (brown). Hematoxylin counterstain in blue.

IHC: Anti-TIGIT antibody conjugate [BLR047F] staining normal tonsil FFPE tissue (brown). Hematoxylin counterstain in blue.

ISP: Anti-TIGIT antibody conjugate [BLR047F] staining normal tonsil FFPE tissue (green). Nuclear counterstain in blue.

References

  1. Mascaux, Céline et al. “Immune evasion before tumour invasion in early lung squamous carcinogenesis.” Nature, vol. 571,7766 (2019): 570-575. DOI: 10.1038/s41586-019-1330-0

Verification

Each lot of antibody conjugate reagent is quality control tested on positive control tissue and reviewed by Ultivue’s Pathology and Biomarker Analytics group to ensure appropriate staining patterns and signal intensity.

This U-VUE Antibody Conjugate is for Research Use Only. Not for Diagnostic purposes.

Contact Us